We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson’s (J&J) single-dose vaccine is far less effective against the Delta and Lambda strains of the SARS-CoV-2 virus than against the original coronavirus, researchers at New York University (NYU) reported. Read More
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) has become the first immunotherapy to succeed in stopping the return of tumors in patients with an aggressive form of early-stage breast cancer. Read More
Despite the disappointing results, BMS still sees strong potential for the combination treatment, noting that it significantly improved survival in six phase 3 trials for five other cancers. Read More
Pfizer and BioNTech announced Thursday that their COVID-19 vaccine is effective against the Delta variant after two doses and that a third dose will boost the protection even more. Read More
CureVac’s messenger-RNA (mRNA)-based COVID-19 vaccine, CVnCoV, was just 48 percent effective in a final analysis from a late-stage trial ― one percentage point higher than reported in an earlier phase 3 analysis and still below the FDA’s 50 percent efficacy threshold required for Emergency Use Authorization. Read More
Sanofi has already partnered with Translate Bio on one mRNA vaccine candidate that uses the same technology as the highly successful Pfizer/BioNTech and Moderna vaccines. Read More